United Therapeutics Q4 Earnings Preview

Posted February 9, 2012

We Recommend...

Contribute to Citybizlist, Share Your News

United Therapeutics (NASDAQ:UTHR) is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. Tuesday, February 14, 2012, the company will report its fourth quarter earnings.

Expectations: Analysts are expecting the company to report earnings of 87 cents per share, up 248% from a year ago, when it reported earnings of 25 cents per share. The consensus estimate is up from three months ago when it was 85 cents, but hasn't changed over the past month. For the fiscal year, analysts are projecting earnings of $3.65 per share. The company's revenue is expected to beat the year-earlier total of $166.5 million by 23.2% to finish at $205.1 million for the quarter. Projected revenue for the fiscal year is $756.2 million.

Performance: The company has enjoyed double-digit year-over-year percentage revenue growth for the past four quarters. Over that period, revenue has grown by an average of 33.2%. The biggest boost came in the fourth quarter of the last fiscal year when revenue increased 52.8% year-over-year. The stock price has risen from $41.68 on November 11, 2011 to $49.90 over the past quarter. United Therapeutics' best recent streak was when its price gained $2.48 per share between December 20, 2011 and December 27, 2011.

Ratings: The majority of analysts (71.4%) give the stock a buy rating. That is still below the mean analyst rating of its nearest 10 competitors, which average 72.1% buys. Analysts' opinions about the stock have worsened recently, as buy ratings have dropped slightly over the last three months.

Earnings estimates provided by Zacks.

United Therapeutics Corp.

To find out more about the company in this article and to see if you
have business connections, click below:

United Therapeutics